Evidence map›Paper›PMID 36099756›Full record

ArticleCytokine2022

Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus.

Maria M Szwarc, Lan Hai, Vineet K Maurya, Kimal Rajapakshe, Dimuthu Perera, Michael M Ittmann, Qianxing Mo, Yong Lin, Matthew L Bettini, Cristian Coarfa and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cytokine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Maria M SzwarcDepartment of Molecular & Cellular Biology, United States.
Lan HaiDepartment of Molecular & Cellular Biology, United States.
Vineet K MauryaDepartment of Molecular & Cellular Biology, United States.
Kimal RajapaksheDepartment of Molecular & Cellular Biology, United States.
Dimuthu PereraDepartment of Molecular & Cellular Biology, United States.
Michael M IttmannDepartment of Pathology, Baylor College of Medicine, Houston, TX, United States.
Qianxing MoDepartment of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Yong LinDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, United States.
Matthew L BettiniDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, United States.
Cristian CoarfaDepartment of Molecular & Cellular Biology, United States.
John P LydonDepartment of Molecular & Cellular Biology, United States. Electronic address: jlydon@bcm.edu.
American Metal Processing (United States) · USUniversity of Utah · USAlbany Molecular Research (United States) · USBaylor College of Medicine · USMoffitt Cancer Center · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
REPRODUCTIVE HORMONES: BIOLOGICAL AND MOLECULAR ACTIONSR01HD008188 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$16.3M
SEX HORMONE RECEPTOR COMPONENTS AND THE CELL GENOMER01HD007857 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$14.6M
Molecular Analysis of Uterine ReceptivityR01HD042311 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LYDON, JOHN P · 2009 to 2023
$4.8M
Self-Reactive T Cell Development in Type 1 DiabetesR01DK114456 · NIDDK · UNIVERSITY OF UTAH · PI BETTINI, MATTHEW · 2018 to 2022
$1.9M
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
NCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NICHD NIH HHS R01 HD007857NICHD NIH HHS R01 HD008188NICHD NIH HHS R01 HD042311NIDDK NIH HHS R01 DK114456
6 · The paper itself

Abstract

Although conventional knockout and transgenic mouse models have significantly advanced our understanding of Receptor Activator of NF-κB Ligand (RANKL) signaling in intra-thymic crosstalk that establishes self-tolerance and later stages of lymphopoiesis, the unique advantages of conditional mouse transgenesis have yet to be explored. A main advantage of conditional transgenesis is the ability to express a transgene in a spatiotemporal restricted manner, enabling the induction (or de-induction) of transgene expression during predetermined stages of embryogenesis or during defined postnatal developmental or physiological states, such as puberty, adulthood, and pregnancy. Here, we describe the K5: RANKL bigenic mouse, in which transgene derived RANKL expression is induced by doxycycline and targeted to cytokeratin 5 positive medullary thymic epithelial cells (mTECs). Short-term doxycycline induction reveals that RANKL transgene expression is significantly induced in the thymic medulla and only in response to doxycycline. Prolonged doxycycline induction in the K5: RANKL bigenic results in a significantly enlarged thymus in which mTECs are hyperproliferative. Flow cytometry showed that there is a marked enrichment of CD4+ and CD8+ single positive thymocytes with a concomitant depletion of CD4+ CD8+ double positives. Furthermore, there is an increase in the number of FOXP3+ T regulatory (Treg) cells and Ulex Europaeus Agglutinin 1+ (UEA1+) mTECs. Transcriptomics revealed that a remarkable array of signals-cytokines, chemokines, growth factors, transcription factors, and morphogens-are governed by RANKL and drive in part the K5: RANKL thymic phenotype. Extended doxycycline administration to 6-weeks results in a K5: RANKL thymus that begins to display distinct histopathological features, such as medullary epithelial hyperplasia, extensive immune cell infiltration, and central tissue necrosis. As there are intense efforts to develop clinical approaches to restore thymic medullary function in the adult to treat immunopathological conditions in which immune cell function is compromised following cancer therapy or toxin exposure, an improved molecular understanding of RANKL's involvement in thymic medulla enlargement will be required. We believe the versatility of the conditional K5: RANKL mouse represents a tractable model system to assist in addressing this requirement as well as many other questions related to RANKL's role in thymic normal physiology and disease processes.

Indexed as

DoxycyclineTranscriptomeAgglutininsAnimalsCytokinesEpithelial CellsForkhead Transcription FactorsKeratin-5LigandsMiceMice, TransgenicNF-kappa BPhenotypeRANK LigandReceptor Activator of Nuclear Factor-kappa BThymus GlandAgglutininsCytokinesDoxycyclineForkhead Transcription FactorsKeratin-5LigandsNF-kappa BRANK LigandReceptor Activator of Nuclear Factor-kappa BTnfsf11 protein, mouseCortexCytokeratin 5DoxycyclineMedullaMouseRANKLRNA-seqThymusTranscriptome

Identifiers

PMID36099756
PMCPMC10255830
OpenAlexW4295760811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.